systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-310Research ArticleОБЗОРЫНовое поколение блокаторов рецепторов ангиотензинаПодзолковВ. И.noemail@neicon.ruТарзимановаА. И.tarzimanova@mail.ruГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииRussian Federation2013231220221038085Copyright © Подзолков В.И., Тарзиманова А.И., 20222022Подзолков В.И., Тарзиманова А.И.Подзолков В.И., Тарзиманова А.И.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/310

Блокаторы рецепторов ангиотензина (БРА) являются одним из основных классов лекарственных препаратов, применяемых в кардиологии. БРА II поколения – это бифункциональные лекарственные препараты, которые не только блокируют рецепторы ангиотензина 1-го типа, но и оказывают влияние на патогенетические механизмы нарушения обмена углеводов и липидов. Родоначальник II поколения БРА – телмисартан, первый и пока единственный из сартанов II поколения, разрешенный в настоящее время для лечения больных с сердечно-сосудистыми заболеваниями. Лечение телмисартаном пациентов с артериальной гипертензией позволяет эффективно контролировать артериальное давление с достижением его целевого уровня, обеспечивает органопротекцию на разных этапах сердечно-сосудистого континуума, снижает риск развития сердечно-сосудистых заболеваний и смерти от них. Наличие дополнительных свойств и плейотропной активности препарата определяет широкий спектр его применения в кардиологии.

телмисартанблокаторы рецепторов ангиотензина нового поколенияPPAR-g-рецепторыReferencesDzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121 (4 Pt 1): 1244–63.Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121 (4 Pt 1): 1244–63.Victor J Dzau, Elliott M Antman, Henry R Black et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114 (25): 2850–70.Victor J Dzau, Elliott M Antman, Henry R Black et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114 (25): 2850–70.ESH–ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.ESH–ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии. 2010; 3: 3–25.Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии. 2010; 3: 3–25.Burnier M, Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.Burnier M, Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.Мунгер М.А. Терапия блокаторами рецепторов ангиотензина и кардиоваскулярная протекция. Современная доказательная база и перспективы развития. Кардиоваск. терапия и профилактика. 2011; 10 (7): 93–104.Мунгер М.А. Терапия блокаторами рецепторов ангиотензина и кардиоваскулярная протекция. Современная доказательная база и перспективы развития. Кардиоваск. терапия и профилактика. 2011; 10 (7): 93–104.Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы? Системные гипертензии. 2010; 4: 5–9.Чазова И.Е., Ратова Л.Г. Первое поколение сартанов: есть ли перспективы? Системные гипертензии. 2010; 4: 5–9.Yusuf S, Teo K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.Yusuf S, Teo K, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.Maillard M, Wurzner G, Nussberger J et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002; 71: 68–76.Maillard M, Wurzner G, Nussberger J et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002; 71: 68–76.Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. Lancet 2007; 369: 201–7.Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta - analysis. Lancet 2007; 369: 201–7.Gress T, Nieto F, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905–12.Gress T, Nieto F, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905–12.Kjeldsen S, Naditch-Brule L, Perlini S et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardio - metabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008; 26: 2064–70.Kjeldsen S, Naditch-Brule L, Perlini S et al. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardio - metabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008; 26: 2064–70.Shargorodsky M, Hass E, Boaz M et al. High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering. Atherosclerosis 2008; 197: 303–10.Shargorodsky M, Hass E, Boaz M et al. High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering. Atherosclerosis 2008; 197: 303–10.Tham D.M, Yi-Xin Wang, Rutledge J.C. Modulation of Vascular Inflammation by PPARs. Drug News Perspect 2003; 16 (2): 109.Tham D.M, Yi-Xin Wang, Rutledge J.C. Modulation of Vascular Inflammation by PPARs. Drug News Perspect 2003; 16 (2): 109.The TRANSCEND investigators. Effects of the angiotensin - receptor blocker telmisartan on cardiovascular events in high - risk patients intolerant to angiotensin - converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372: 1174–83.The TRANSCEND investigators. Effects of the angiotensin - receptor blocker telmisartan on cardiovascular events in high - risk patients intolerant to angiotensin - converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372: 1174–83.Burnier M, Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.Burnier M, Brunner H.R. Angiotensin II receptor antagonists. Lancet 2000; 355: 637–45.Brunner H.R. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16 (Suppl. 2): S13–6.Brunner H.R. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. J Hum Hypertens 2002; 16 (Suppl. 2): S13–6.Kakuta H et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41–6.Kakuta H et al. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. Int J Clin Pharmacol Res 2005; 25: 41–6.Wienen W et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245–52.Wienen W et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245–52.Benndorf R, Appel D, Maas R et al. Telmisartan improves endothelial function in patient with essential hypertention. J Cardiovasc Farmacol 2007; 50: 367–71.Benndorf R, Appel D, Maas R et al. Telmisartan improves endothelial function in patient with essential hypertention. J Cardiovasc Farmacol 2007; 50: 367–71.Tomiyama H, Yamatada J, Koji Y et al. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dymetil - arginine levels. Am J Hypertens 2007; 20: 1305–11.Tomiyama H, Yamatada J, Koji Y et al. Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dymetil - arginine levels. Am J Hypertens 2007; 20: 1305–11.Takai S, Kirimura K et al. Significance of angiotensin II receptor blocker lipophillicities and there protective effects against vascular remodeling. Hipertens Res 2005; 28: 593–600.Takai S, Kirimura K et al. Significance of angiotensin II receptor blocker lipophillicities and there protective effects against vascular remodeling. Hipertens Res 2005; 28: 593–600.Williams B, Gosse P, Lowe L. PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24: 193–200.Williams B, Gosse P, Lowe L. PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24: 193–200.Lacourcire Y, Neutel J.M, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild - to - moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19: 104–12.Lacourcire Y, Neutel J.M, Davidai G, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild - to - moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19: 104–12.Gosse P, Neutel J.M, Schumacher H et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 2007; 12: 141–7.Gosse P, Neutel J.M, Schumacher H et al. The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. Blood Press Monit 2007; 12: 141–7.Williams B, Lacourcire Y, Schumacher H et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009; 23 (9): 610–9.Williams B, Lacourcire Y, Schumacher H et al. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens 2009; 23 (9): 610–9.Sharma A.M, Davidson J.A, Gavin J.R III, De Sousa N.J. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high - risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension 2005; 46: 898–9.Sharma A.M, Davidson J.A, Gavin J.R III, De Sousa N.J. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high - risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension 2005; 46: 898–9.Ragot S, Ezzaher A, Meunier A et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16 (12): 865–73.Ragot S, Ezzaher A, Meunier A et al. Comparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE study. J Hum Hypertens 2002; 16 (12): 865–73.Lacourciere I. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group. Int J Clin Pract 1999; 53: 99–103.Lacourciere I. The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group. Int J Clin Pract 1999; 53: 99–103.The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.The ONTARGET investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.Song J.C, White C.M. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001; 36: 487–99.Song J.C, White C.M. Olmesartan medoxomil (CS-866). An angiotensin II receptor blocker for treatment of hypertension. Formulary 2001; 36: 487–99.Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy – rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677–86.Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy – rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin ii receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) Study. J Int Med Res 2005; 33: 677–86.Barnett A.H, Bain S.C, Bouter P et al. Diabetics exposed to telmisartan and enalapril study group. Angiotensin - receptor blockade versus converting - enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351 (19): 1952–61.Barnett A.H, Bain S.C, Bouter P et al. Diabetics exposed to telmisartan and enalapril study group. Angiotensin - receptor blockade versus converting - enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351 (19): 1952–61.Galle J, Schwedhelm E, Pinnetti S et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23 (10): 3174–83.Galle J, Schwedhelm E, Pinnetti S et al. VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23 (10): 3174–83.Bichu P, Nistala R, Khan A et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009; 5: 129–40.Bichu P, Nistala R, Khan A et al. Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag 2009; 5: 129–40.Schmieder R.E, Delles C, Mimran A et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30 (6): 1351–6.Schmieder R.E, Delles C, Mimran A et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30 (6): 1351–6.Sharma A.M, Hollander A, Koster J; on behalf of the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) Study Group. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63 (4): 250–7.Sharma A.M, Hollander A, Koster J; on behalf of the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) Study Group. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63 (4): 250–7.Ратова Л.Г., Чазова И.Е. Влияние антигипертензивной терапии микардисом плюс на функцию почек (клинический пример). Системные гипертензии. 2010; 2: 66–70.Ратова Л.Г., Чазова И.Е. Влияние антигипертензивной терапии микардисом плюс на функцию почек (клинический пример). Системные гипертензии. 2010; 2: 66–70.

The authors declare that there are no conflicts of interest present.